verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh20083-429-33verezdo-8537Research ArticleСтатьиArticlesМетаболические эффекты пролактинаMetabolicheskie effekty prolaktinaДзерановаЛ КDzeranovaL K-МокрышеваН ГMokryshevaN G-БарминаИ ИBarminaI I-ГиниятуллинаЕ НGiniyatullinaE N-ФГУ Эндокринологический научный центр Росмедтехнологий20081512200803-4№3-4 (2008)2933Copyright © Дзеранова Л.К., Мокрышева Н.Г., Бармина И.И., Гиниятуллина Е.Н., 20082008Дзеранова Л.К., Мокрышева Н.Г., Бармина И.И., Гиниятуллина Е.Н.Dzeranova L.K., Mokrysheva N.G., Barmina I.I., Giniyatullina E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/8537

Первые описания характерных для гиперпролактинемии симптомов встречаются в еще древних трактатах, в том числе в трудах Гиппократа. Попытка объединить ряд клинических особенностей в одну нозологическую форму была сделана в XIX веке. Было отмечено, что у рожавших женщин после прекращения грудного вскармливания могут длительно сохраняться лактация, отсутствовать менструации и отмечаться дегенеративные изменения полового тракта. Указанный симптомокомплекс был назван синдромом Киари–Фроммеля [1].В середине хх века Argonz и del Castillo описал вариант данного заболевания у ранее бесплодных женщин и высказал предположение о гормональной природе выявленных нарушений.

ReferencesДедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М 2004.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М 2004.Bole-Feysot C., Goffin V., Edery M. et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19 (3): 225–268.Bole-Feysot C., Goffin V., Edery M. et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19 (3): 225–268.Курляндская Р.И., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч врач 2004; 1: 6-9.Курляндская Р.И., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч врач 2004; 1: 6-9.Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48 (5): 547–553.Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48 (5): 547–553.Baptista T., Lacruz A., Meza T. et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 2001; 46 (9): 829–834.Baptista T., Lacruz A., Meza T. et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 2001; 46 (9): 829–834.Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 1982; 16 (4): 383–390.Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 1982; 16 (4): 383–390.Kiriakov A., Bulatov A.A., Elizarova G.P., Kavrykova I., Tinterova Z., Angelova S., Zaitseva N.S., Pankov I.A. Change in the blood lipoprotein spectrum in experimental Hyperprolactinemia. Probl Endokrinol (Mosk) 1991; 37 (1): 44–46.Kiriakov A., Bulatov A.A., Elizarova G.P., Kavrykova I., Tinterova Z., Angelova S., Zaitseva N.S., Pankov I.A. Change in the blood lipoprotein spectrum in experimental Hyperprolactinemia. Probl Endokrinol (Mosk) 1991; 37 (1): 44–46.Heil S.H. Sex-specific effects of prolactin on food intake by rats. Horm Behav 1999; 35 (1): 47–54.Heil S.H. Sex-specific effects of prolactin on food intake by rats. Horm Behav 1999; 35 (1): 47–54.Moore B.J., Gerardo-Gettens T., Horwitz B.A., Stern J.S. Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 1986; 17 (4): 563–569.Moore B.J., Gerardo-Gettens T., Horwitz B.A., Stern J.S. Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 1986; 17 (4): 563–569.Brandebourg T.D., Bown J.L., Ben-Jonathan N. Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue. Biochem Biophys Res Commun 2007; 357 (2) 408–413.Brandebourg T.D., Bown J.L., Ben-Jonathan N. Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue. Biochem Biophys Res Commun 2007; 357 (2) 408–413.Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology 2001; 142 (11): 480–490.Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology 2001; 142 (11): 480–490.McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996; 137: 5723–5726.McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996; 137: 5723–5726.Varma M. Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav 1999; 68 (12): 99–107.Varma M. Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav 1999; 68 (12): 99–107.Heshmati H.M., Turpin G., de Gennes J.L. Chronic hyperprolactinemia and plasma lipids in women. Klin Wochenschr 1987; 65 (11): 516–519.Heshmati H.M., Turpin G., de Gennes J.L. Chronic hyperprolactinemia and plasma lipids in women. Klin Wochenschr 1987; 65 (11): 516–519.Baptista T., Contreras Q., Teneud L. et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatr 1998;22 (1): 187–198.Baptista T., Contreras Q., Teneud L. et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatr 1998;22 (1): 187–198.Noel M.B., Woodside B. Effects of systemic and central prolactin injections on food intake, weight gain, and estrous cyclicity in female rats. Physiol Behav 1993; 54 (1): 151–154.Noel M.B., Woodside B. Effects of systemic and central prolactin injections on food intake, weight gain, and estrous cyclicity in female rats. Physiol Behav 1993; 54 (1): 151–154.Sauve D., Woodside B. Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res 2000; 868 (2): 306–314.Sauve D., Woodside B. Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res 2000; 868 (2): 306–314.Sauve D., Woodside B. The effect of central administration of prolactin on food intake invirgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen. Brain Res 1996; 729 (1): 75–81.Sauve D., Woodside B. The effect of central administration of prolactin on food intake invirgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen. Brain Res 1996; 729 (1): 75–81.Long Jin, Shuya Zhang, Bartolome G. Burguera et al. Leptin and Leptin receptor expression in rat and mouse pituitary cells. J Endocrinology 2000; 141 (1): 333–339.Long Jin, Shuya Zhang, Bartolome G. Burguera et al. Leptin and Leptin receptor expression in rat and mouse pituitary cells. J Endocrinology 2000; 141 (1): 333–339.Cone D.R. Editorial: the ups and downs of leptin action. Endocrinology 1999;140 (11): 4921–4922.Cone D.R. Editorial: the ups and downs of leptin action. Endocrinology 1999;140 (11): 4921–4922.Панков Ю.А. Достижения в исследовании действия лептина на нейроны гипоталамуса. Журн эволюц биохим физиол 2000; 6: 509–514.Панков Ю.А. Достижения в исследовании действия лептина на нейроны гипоталамуса. Журн эволюц биохим физиол 2000; 6: 509–514.Jin H., Nip S., O’Dowd B.F., George S.R. D1 dopamine receptor activity is not altered by a mutation in the first intracellular loop. Biochim Biophys Acta 1998; 1402: (2): 165–170.Jin H., Nip S., O’Dowd B.F., George S.R. D1 dopamine receptor activity is not altered by a mutation in the first intracellular loop. Biochim Biophys Acta 1998; 1402: (2): 165–170.Gualillo O., Lago F., Garcia M. et al. Prolactin Stimulates Leptin Secretion by Rat White Adipose Tissue. Endocrinology 1999; 140 (11): 5149–5153.Gualillo O., Lago F., Garcia M. et al. Prolactin Stimulates Leptin Secretion by Rat White Adipose Tissue. Endocrinology 1999; 140 (11): 5149–5153.Doknic M., Pekic S., Zarkovic M., Medic-Stojanoska M., Dieguez C., Casanueva F., Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147 (1): 77–84.Doknic M., Pekic S., Zarkovic M., Medic-Stojanoska M., Dieguez C., Casanueva F., Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147 (1): 77–84.Mарова Е.И. Нейроэндокринология. Ярославль 1999; 506.Mарова Е.И. Нейроэндокринология. Ярославль 1999; 506.Yoshimura A., Ohkubo T., Kiguchi T. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14 (12): 2816–2826.Yoshimura A., Ohkubo T., Kiguchi T. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14 (12): 2816–2826.Isidori A.M., Strollo F., More M. et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85 (5): 1954–1962.Isidori A.M., Strollo F., More M. et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85 (5): 1954–1962.Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17 (3): 110–116.Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17 (3): 110–116.Fleenor D.E., Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology 2001; 142 (7): 2805–2810.Fleenor D.E., Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology 2001; 142 (7): 2805–2810.Fleenor D., Arumugam R., Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res 2006; 66 (3): 101–110.Fleenor D., Arumugam R., Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res 2006; 66 (3): 101–110.De Courten M., Zimmet P., Hodge A. et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997; 14 (3): 200–208.De Courten M., Zimmet P., Hodge A. et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997; 14 (3): 200–208.Tuzcu A., Bahceci M., Dursun M. et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003; 26 (4): 341–346.Tuzcu A., Bahceci M., Dursun M. et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003; 26 (4): 341–346.Bahceci M., Tuzcu A., Bahceci S., Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003; 26 (7): 655–659.Bahceci M., Tuzcu A., Bahceci S., Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003; 26 (7): 655–659.Cincotta A.H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19 (Issue 6): 667–670.Cincotta A.H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19 (Issue 6): 667–670.Fahy U., Hopton M.I., Hartog M. et al. The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Hum Reprod 1999; 14 (2): 285–287.Fahy U., Hopton M.I., Hartog M. et al. The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Hum Reprod 1999; 14 (2): 285–287.Korner J., Lo J., Freda P.U., Wardlaw S.L. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obes Res 2003; 11: 311–312.Korner J., Lo J., Freda P.U., Wardlaw S.L. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obes Res 2003; 11: 311–312.Bina K.G., Cincotta A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71 (1): 68–78.Bina K.G., Cincotta A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71 (1): 68–78.Pijl H., Ohashi S., Matsuda M. et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23 (Issue 8): 1154–1161.Pijl H., Ohashi S., Matsuda M. et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23 (Issue 8): 1154–1161.

The authors declare that there are no conflicts of interest present.